Cindy Chu
Clinical researcher
Cindy’s main research area is in Plasmodium vivax malaria. She has conducted studies on the epidemiology of P. vivax recurrence as well as efficacy trials with the schizonticidal agents chloroquine and dihydroartemisinin-piperaquine. Her current focus is on the radical curative treatment of P. vivax using 8-aminoquinolines and the haemolytic effects of this class of drugs in G6PD heterozygous females. The goal of this research is for the safe delivery of primaquine and tafenoquine for treatment of P. vivax malaria and within the context of P. vivax elimination.
SMRU free healthcare
Chloroquine and primaquine induced haematocrit changes to G6PD heterozygote
Plasmodium vivax recurrences
Recent publications
-
Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'.
Journal article
Watson JA. et al, (2024), Elife, 13
-
Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers.
Journal article
Pukrittayakamee S. et al, (2024), Elife, 12
-
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.
Journal article
Commons RJ. et al, (2024), Lancet Infect Dis, 24, 172 - 183